Rule 2.7, 3.10.3, 3.10.4, 3.10.5

## Appendix 3B

# New issue announcement, application for quotation of additional securities and agreement

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

 $Introduced\ 01/07/96\ \ Origin:\ Appendix\ 5\ \ Amended\ 01/07/98,\ 01/09/99,\ 01/07/00,\ 30/09/01,\ 11/03/02,\ 01/01/03,\ 24/10/05,\ 01/08/12$ 

Name of	entity		
CYNATA THERAPEUTICS LIMITED			
ABN			
98 104	037 372		
We (th	e entity) give ASX the following	ng information.	
Part 1 - All issues You must complete the relevant sections (attach sheets if there is not enough space).			
1	<sup>+</sup> Class of <sup>+</sup> securities issued or to be issued	Fully Paid Ordinary Shares	
2	Number of *securities issued or to be issued (if known) or maximum number which may be issued	10,000	
3	Principal terms of the <sup>+</sup> securities (eg, if options, exercise price and expiry date; if partly paid <sup>+</sup> securities, the amount outstanding and due dates for payment; if <sup>+</sup> convertible securities, the conversion price and dates for conversion)	Fully Paid Ordinary Shares	

<sup>+</sup> See chapter 19 for defined terms.

4	Do the *securities rank equally in all respects from the date of allotment with an existing *class of quoted *securities?	Yes – the shares rank equally in all respects from the date of issue with the existing quoted Fully Paid Ordinary Shares of the Company.
	If the additional securities do not rank equally, please state:  • the date from which they do  • the extent to which they participate for the next dividend, (in the case of a trust, distribution) or interest payment  • the extent to which they do not rank equally, other than in relation to the next dividend, distribution or interest payment	
5	Issue price or consideration	\$0.20 per share
6	Purpose of the issue (If issued as consideration for the acquisition of assets, clearly identify those assets)	Exercise of Listed 31/12/14 Options.
6a	Is the entity an <sup>+</sup> eligible entity that has obtained security holder approval under rule 7.1A?	Yes
	If Yes, complete sections 6b – 6h <i>in</i> relation to the *securities the subject of this Appendix 3B, and comply with section 6i	
6b	The date the security holder resolution under rule 7.1A was passed	29 October 2013
6c	Number of *securities issued without security holder approval under rule 7.1	Nil
6d	Number of *securities issued with security holder approval under rule 7.1A	Nil
6e	Number of *securities issued with security holder approval under rule 7.3, or another specific security holder approval (specify date of meeting)	Nil

<sup>+</sup> See chapter 19 for defined terms.

6f	Number of securities issued under an exception in rule 7.2	10,000	
6g	If securities issued under rule 7.1A, was issue price at least 75% of 15 day VWAP as calculated under rule 7.1A.3? Include the issue date and both values. Include the source of the VWAP calculation.	N/A	
6h	If securities were issued under rule 7.1A for non-cash consideration, state date on which valuation of consideration was released to ASX Market Announcements	N/A	
6i	Calculate the entity's remaining issue capacity under rule 7.1 and rule 7.1A – complete Annexure 1 and release to ASX Market Announcements	7.1 7,024,182 7.1A 5,495,398	
7	Dates of entering *securities into uncertificated holdings or despatch of certificates	26 September 2014	
		Number	+Class
8	Number and +class of all +securities quoted on ASX ( <i>including</i> the securities in section 2 if applicable)	44,972,902	Ordinary Fully Paid Shares (CYP)
	11	11,098,500	Options exercise price \$0.20 expiring 31 December 2014 (CYPO)

<sup>+</sup> See chapter 19 for defined terms.

Number +Class 9 10.000.001 Fully Paid Ordinary Shares Number and +class of all +securities not quoted on ASX (including the (CYPAA) escrowed until securities in section 2 if applicable) 22 November 2014. 500.000 Unlisted Options exercise price \$0.40, expiring 9 September 2016 (CYPAK) - escrowed until 29 November 2015. 5,000,000 Unlisted Options exercise price \$0.40, expiring 27 September 2018 (subject to vesting conditions) (CYPAI) - escrowed until 29 November 2015. 200,000 Unlisted Options exercise price \$0.40, expiring 30 November 2015 (vesting on 29 May 2015). 1,000,000 Unlisted Options exercise price \$0.40, expiring 30 November 2015 (vesting on 1 December 2014). 10 Dividend policy (in the case of a N/A trust, distribution policy) on the increased capital (interests) Part 2 - Bonus issue or pro rata issue 11 Is security holder approval required? 12 Is the issue renounceable or nonrenounceable? 13 Ratio in which the +securities will be offered 14 +Class of +securities to which the offer relates 15 +Record date determine to entitlements

Will holdings on different registers (or subregisters) be aggregated for

calculating entitlements?

16

<sup>+</sup> See chapter 19 for defined terms.

17	Policy for deciding entitlements in relation to fractions	
18	Names of countries in which the entity has *security holders who will not be sent new issue documents  Note: Security holders must be told how their entitlements are to be dealt with.  Cross reference: rule 7.7.	
19	Closing date for receipt of acceptances or renunciations	
20	Names of any underwriters	
21	Amount of any underwriting fee or commission	
22	Names of any brokers to the issue	
23	Fee or commission payable to the broker to the issue	
24	Amount of any handling fee payable to brokers who lodge acceptances or renunciations on behalf of +security holders	
25	If the issue is contingent on *security holders' approval, the date of the meeting	
26	Date entitlement and acceptance form and prospectus or Product Disclosure Statement will be sent to persons entitled	
27	If the entity has issued options, and the terms entitle option holders to participate on exercise, the date on which notices will be sent to option holders	
28	Date rights trading will begin (if applicable)	
29	Date rights trading will end (if applicable)	

<sup>+</sup> See chapter 19 for defined terms.

30	How do <sup>+</sup> security holders sell their entitlements <i>in full</i> through a broker?
31	How do *security holders sell <i>part</i> of their entitlements through a broker and accept for the balance?
32	How do *security holders dispose of their entitlements (except by sale through a broker)?
33	<sup>+</sup> Despatch date
	3 - Quotation of securities d only complete this section if you are applying for quotation of securities
34	Type of securities (tick one)
(a)	X Securities described in Part 1
(b)	All other securities  Example: restricted securities at the end of the escrowed period, partly paid securities that become fully paid, employed incentive share securities when restriction ends, securities issued on expiry or conversion of convertible securities
Entiti	es that have ticked box 34(a)
Additi	ional securities forming a new class of securities
Tick t docum	o indicate you are providing the information or tents
35	If the *securities are *equity securities, the names of the 20 largest holders of the additional *securities, and the number and percentage of additional *securities held by those holders
36	If the *securities are *equity securities, a distribution schedule of the additional *securities setting out the number of holders in the categories  1 - 1,000  1,001 - 5,000  5,001 - 10,000  10,001 - 100,000  100,001 and over
37	A copy of any trust deed for the additional *securities

<sup>+</sup> See chapter 19 for defined terms.

Entitie	s that have ticked box 34(b)		
38	Number of securities for which <sup>+</sup> quotation is sought		
39	Class of *securities for which quotation is sought		
40	Do the *securities rank equally in all respects from the date of allotment with an existing *class of quoted *securities?		
	If the additional securities do not rank equally, please state:  • the date from which they do  • the extent to which they participate for the next dividend, (in the case of a trust, distribution) or interest payment  • the extent to which they do not rank equally, other than in relation to the next dividend, distribution or interest payment		
41	Reason for request for quotation now Example: In the case of restricted securities, end of restriction period		
	(if issued upon conversion of another security, clearly identify that other security)		
42	Number and +class of all +securities quoted on ASX (including the securities in clause 38)	Number	+Class

<sup>+</sup> See chapter 19 for defined terms.

#### **Quotation agreement**

- <sup>+</sup>Quotation of our additional <sup>+</sup>securities is in ASX's absolute discretion. ASX may quote the <sup>+</sup>securities on any conditions it decides.
- We warrant the following to ASX.
  - The issue of the \*securities to be quoted complies with the law and is not for an illegal purpose.
  - There is no reason why those \*securities should not be granted \*quotation.
  - An offer of the \*securities for sale within 12 months after their issue will not require disclosure under section 707(3) or section 1012C(6) of the Corporations Act.

Note: An entity may need to obtain appropriate warranties from subscribers for the securities in order to be able to give this warranty

- Section 724 or section 1016E of the Corporations Act does not apply to any applications received by us in relation to any \*securities to be quoted and that no-one has any right to return any \*securities to be quoted under sections 737, 738 or 1016F of the Corporations Act at the time that we request that the \*securities be quoted.
- If we are a trust, we warrant that no person has the right to return the \*securities to be quoted under section 1019B of the Corporations Act at the time that we request that the \*securities be quoted.
- We will indemnify ASX to the fullest extent permitted by law in respect of any claim, action or expense arising from or connected with any breach of the warranties in this agreement.
- We give ASX the information and documents required by this form. If any information or document not available now, will give it to ASX before †quotation of the †securities begins. We acknowledge that ASX is relying on the information and documents. We warrant that they are (will be) true and complete.

Date: 26 September 2014 (Director/Company secretary)

Print name: Peter Webse

== == == ==

<sup>+</sup> See chapter 19 for defined terms.

## Appendix 3B – Annexure 1

## Calculation of placement capacity under rule 7.1 and rule 7.1A for +eligible entities

Introduced 01/08/12

#### Part 1

Rule 7.1 – Issues exceeding 15% of capital			
Step 1: Calculate "A", the base figure from which the placement capacity is calculated			
Insert number of fully paid ordinary securities on issue 12 months before date of issue or agreement to issue	31,798,743 (Adjusted to post consolidation)		
Add the following:			
Number of fully paid ordinary securities issued in that 12 month period under an exception in rule 7.2	589,042	Exercise of Options (adjusted to post consolidation)	
Number of fully paid ordinary	22,500,001	22 November 2013	
securities issued in that 12 month period with shareholder approval	66,201	Exercise of Options	
Number of partly paid ordinary securities that became fully paid in that 12 month period			
Note: Include only ordinary securities here – other classes of equity securities cannot be added Include here (if applicable) the securities the subject of the Appendix 3B to which this form is annexed It may be useful to set out issues of securities on different dates as separate line items			
<b>Subtract</b> the number of fully paid ordinary securities cancelled during that 12 month period	-		
"A"	54,953,987		

<sup>+</sup> See chapter 19 for defined terms.

a			
Step 2: Calculate 15% of "A"			
"B"	0.15		
	[Note: this	s value cannot be changed]	
<b>Multiply</b> "A" by 0.15	8,243,098		
Step 3: Calculate "C", the amount of placement capacity under rule 7.1 that has already been used			
Insert number of equity securities issued or agreed to be issued in that 12 month period not counting those issued:	18,916	Ordinary Fully Paid Shares issued on 2 October 2013 (adjusted to post consolidation)	
Under an exception in rule 7.2	800,000	Unlisted Options issued on 29 May 2014	
Under rule 7.1A	400 000	•	
With security holder approval under rule 7.1 or rule 7.4	400,000	Unlisted Options issued on 11 September 2014	
<ul> <li>Note:</li> <li>This applies to equity securities, unless specifically excluded – not just ordinary securities</li> <li>Include here (if applicable) the securities the subject of the Appendix 3B to which this form is annexed</li> <li>It may be useful to set out issues of securities on different dates as separate line items</li> </ul>			
"C"	1,218,916		
Step 4: Subtract "C" from ["A" x "B"] to calculate remaining placement capacity under rule 7.1			
"A" x 0.15	8,243,098	1	
Note: number must be same as shown in Step 2			
Subtract "C"	1,218,916		
Note: number must be same as shown in Step 3			
<b>Total</b> ["A" x 0.15] – "C"	7,024,182		
	[Note: this is the remaining placement capacity under rule 7.1]		

<sup>+</sup> See chapter 19 for defined terms.

### Part 2

Rule 7.1A – Additional placement capacity for eligible entities		
Step 1: Calculate "A", the base figure from which the placement capacity is calculated		
54,953,987		
0.10 Note: this value cannot be changed		
5,495,398		
Step 3: Calculate "E", the amount of placement capacity under rule 7.1A that has already been used		
-		

<sup>+</sup> See chapter 19 for defined terms.

Step 4: Subtract "E" from ["A" x "D"] to calculate remaining placement capacity under rule 7.1A		
"A" x 0.10  Note: number must be same as shown in Step 2	5,495,398	
Subtract "E"  Note: number must be same as shown in Step 3	-	
<i>Total</i> ["A" x 0.10] – "E"	5,495,398  Note: this is the remaining placement capacity under rule 7.1A	

<sup>+</sup> See chapter 19 for defined terms.